GlassScriptPhysician profile
George Neiderman
NPI 1346328713
$108,572.71
in general payments reported to CMS, 2019-2025
20 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $382 · 2021: $30K · 2022: $23K · 2023: $47K · 2024: $7,498 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Travel and Lodging: $3,485 · Food and Beverage: $3,261 · Consulting Fee: $1,348 · Education: $94.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,650.00 |
| Travel and Lodging | $3,485.21 |
| Food and Beverage | $3,260.75 |
| Consulting Fee | $1,348.00 |
| Education | $94.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $106,760.47 | 2019-2025 | Lokelma, Farxiga |
| Fresenius USA Marketing, INC. | $348.93 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $241.01 | 2024-2025 | Terlivaz |
| Akebia Therapeutics INC | $170.72 | 2019-2021 | |
| Glaxosmithkline, LLC. | $170.02 | 2021-2025 | Benlysta |
| Amgen INC. | $152.23 | 2019-2020 | |
| Novo Nordisk INC | $125.43 | 2019-2025 | Ozempic |
| Alexion Pharmaceuticals, INC. | $112.00 | 2020 | |
| Apellis Pharmaceuticals, INC. | $104.21 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.12 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $54.36 | 2022-2023 | Lupkynis |
| Calliditas Therapeutics US INC. | $43.16 | 2025 | Tarpeyo |
| Vifor Pharma, INC. | $40.78 | 2021 | |
| Avanir Pharmaceuticals, INC. | $36.93 | 2019 | |
| Bard Peripheral Vascular, INC. | $32.69 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.75 | 2020 | |
| Travere Therapeutics, INC. | $20.90 | 2024-2025 | Filspari |
| Currax Pharmaceuticals LLC | $17.25 | 2021 | |
| Merck Sharp & Dohme LLC | $16.34 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Neiderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.